Premium
Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model
Author(s) -
ElGogo Susanne,
Staib Caroline,
Lasarte Juan José,
Sutter Gerd,
Adler Heiko
Publication year - 2008
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.1144
Subject(s) - virology , ns3 , immunogenicity , vaccinia , antigen , immunization , hepatitis c virus , virus , biology , vaccination , recombinant virus , recombinant dna , heterologous , immunology , biochemistry , gene
Background Efficient vaccines against hepatitis C virus (HCV) infection are urgently needed. Vaccine development has been hampered by the lack of suitable small animal models to reliably test the protective capacity of immmunization. Methods We used recombinant murine gammaherpesvirus 68 (MHV‐68) as a novel challenge virus in mice and tested the efficacy of heterologous candidate human vaccines based on modified vaccinia virus Ankara or adenovirus, both delivering HCV non‐structural NS3 or core proteins. Results Recombinant MHV‐68 expressing NS3 (MHV‐68‐NS3) or core (MHV‐68‐core) were constructed and characterized in vitro and in vivo . Mice immunized with NS3‐specific vector vaccines and challenged with MHV‐68‐NS3 were infected but showed significantly reduced viral loads in the acute and latent phase of infection. NS3‐specific CD8+ T cells were amplified in immunized mice after challenge with MHV‐68‐NS3. By contrast, we did neither detect a reduction of viral load nor an induction of core‐specific CD8+ T cells after core‐specific immunization. Conclusions Our data suggest that the challenge system using recombinant MHV‐68 is a highly suitable model to test the immunogenicity and protective capacity of HCV candidate vaccine antigens. Using this system, we demonstrated the usefulness of NS3‐specific immunization. By contrast, our analysis rather discarded core as a vaccine antigen. Copyright © 2007 John Wiley & Sons, Ltd.